The FDA has accepted the NDA for ulixacaltamide HCl, a selective T-type calcium channel inhibitor for essential tremor, following positive phase 3 Essential3 trial results.

A Quakertown police report offers new details on why officers couldn't identify the source of a gun threat tip ahead of the ...

AttackIQ has released a new attack graph that emulates the behaviors of NightSpire Ransomware, a financially motivated ...

Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clinical study program, including an extrapolation of efficacy data showing that Dupixent significantly ...

The Ohio Environmental Protection Agency issued a Notice of Violation letter Monday to the village of McDonald. Based on a ...

Nephrologists now have an approved treatment option for FSGS patients without nephrotic syndrome following the latest FDA ...

A series of infrastructure projects, staffing moves, and public safety initiatives moved forward this week as the Yates ...

If there were an easier way to get the benefits of a squat or a pull up without having to actually do a squat or a pull-up, ...

In the past 18 months, the FDA has outlined clear guidelines for designing, documenting, updating, and monitoring AI-powered ...

In a 3,000-square-meter facility built on the grounds of a decommissioned steelworks in Beijing’s Shijingshan district, ...

STEINERT will be presenting new and advanced sorting solutions at IFAT 2026 (4–7 May in Munich) at Stand 451/552 in Hall B6. The focus will be on the STEINERT PLASMAX, with an upgrade of the LIBS ...

Batoclimab missed the primary endpoint of proptosis reduction at week 24 in two phase 3 studies of adults with active thyroid eye disease.